Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free NMTR Stock Alerts

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo
Compare

NMTR vs. INDP, SXTP, AKTX, ALZN, and SNGX

Should you buy 9 Meters Biopharma stock or one of its competitors? MarketBeat compares 9 Meters Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 9 Meters Biopharma include Indaptus Therapeutics (INDP), 60 Degrees Pharmaceuticals (SXTP), Akari Therapeutics (AKTX), Alzamend Neuro (ALZN), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry.

How does 9 Meters Biopharma compare to Indaptus Therapeutics?

9 Meters Biopharma (NASDAQ:NMTR) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

9 Meters Biopharma's return on equity of -584.97% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
Indaptus Therapeutics N/A -1,030.07%-299.69%

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
Indaptus Therapeutics Neutral

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Indaptus Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

Summary

9 Meters Biopharma beats Indaptus Therapeutics on 6 of the 10 factors compared between the two stocks.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
9 Meters Biopharma N/A -584.97%-159.45%

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

60 Degrees Pharmaceuticals has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 7 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that 9 Meters Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Negative
9 Meters Biopharma Neutral

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.79-$7.36M-$8.92N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 9 of the 15 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Akari Therapeutics' return on equity of -123.29% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -123.29% -63.01%
9 Meters Biopharma N/A -584.97%-159.45%

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 30.7% of Akari Therapeutics shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Akari Therapeutics had 13 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 13 mentions for Akari Therapeutics and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.13 indicating that 9 Meters Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
9 Meters Biopharma Neutral

Akari Therapeutics presently has a consensus target price of $89.00, suggesting a potential upside of 387.14%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Akari Therapeutics is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Akari Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Summary

Akari Therapeutics beats 9 Meters Biopharma on 8 of the 11 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Alzamend Neuro?

9 Meters Biopharma (NASDAQ:NMTR) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Alzamend Neuro is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
Alzamend NeuroN/AN/A-$4.51M-$2.16N/A

Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 2,377.88%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alzamend Neuro
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alzamend Neuro's return on equity of -177.52% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
Alzamend Neuro N/A -177.52%-140.41%

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
Alzamend Neuro Neutral

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Summary

Alzamend Neuro beats 9 Meters Biopharma on 8 of the 11 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Soligenix?

Soligenix (NASDAQ:SNGX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Soligenix's return on equity of -244.73% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
SoligenixN/A -244.73% -131.22%
9 Meters Biopharma N/A -584.97%-159.45%

In the previous week, Soligenix had 6 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 6 mentions for Soligenix and 0 mentions for 9 Meters Biopharma. Soligenix's average media sentiment score of 1.00 beat 9 Meters Biopharma's score of 0.00 indicating that Soligenix is being referred to more favorably in the media.

Company Overall Sentiment
Soligenix Positive
9 Meters Biopharma Neutral

Soligenix has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Soligenix has higher revenue and earnings than 9 Meters Biopharma. Soligenix is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$120K48.18-$11.08M-$1.68N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,438.07%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Soligenix beats 9 Meters Biopharma on 11 of the 14 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Export
Metric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$1.04M$470.74M$6.46B$12.34B
Dividend YieldN/A3.87%2.76%5.28%
P/E Ratio0.003.8620.9925.66
Price / SalesN/A7,437.03560.3086.31
Price / CashN/A13.1343.4956.67
Price / BookN/A85.4310.417.14
Net Income-$43.77M-$96.07M$3.57B$335.98M

9 Meters Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
INDP
Indaptus Therapeutics
0.3288 of 5 stars		$1.81
+3.1%		N/A-88.2%$4.02MN/AN/A6
SXTP
60 Degrees Pharmaceuticals
2.7221 of 5 stars		$1.49
-1.0%		$14.10
+849.5%		-81.6%$3.92M$1.41MN/A3
AKTX
Akari Therapeutics
2.481 of 5 stars		$3.39
+7.6%		$89.00
+2,525.4%		-64.2%$3.88MN/AN/A9
ALZN
Alzamend Neuro
2.9552 of 5 stars		$1.02
-2.3%		$28.00
+2,655.9%		-69.0%$3.86MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel